Compare RMCF & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCF | GRDX |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | 2 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 28.6M |
| IPO Year | 2024 | N/A |
| Metric | RMCF | GRDX |
|---|---|---|
| Price | $1.68 | $6.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.4K | ★ 164.3K |
| Earning Date | 06-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,432,352.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $1.87 |
| 52 Week High | $2.99 | $6.93 |
| Indicator | RMCF | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 29.64 | 71.45 |
| Support Level | $1.48 | $2.16 |
| Resistance Level | $1.82 | $6.93 |
| Average True Range (ATR) | 0.13 | 0.64 |
| MACD | -0.04 | 0.11 |
| Stochastic Oscillator | 11.23 | 78.03 |
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.